Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.23.1
Stockholders' Equity
3 Months Ended
Feb. 28, 2023
Equity [Abstract]  
Stockholders' Equity

Note 7 – Stockholders’ Equity

Employee Stock Incentive Plan

The Company maintains the 2006 Stock Incentive Plan (the “2006 Plan”) under which it has reserved 1,000,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, stock-appreciation rights (commonly referred to as “SARs”) and stock awards (i.e., performance options to purchase shares and performance units). As of February 28, 2023, and November 30, 2022, there were 22,500 and 22,500 options issued, but not yet exercised, under the 2006 Plan, respectively. As of February 28, 2023, there were no shares available for future issuance under the 2006 Plan.

The Company maintains the 2012 Equity Incentive Plan (the “2012 Plan”) which became effective December 1, 2011 as approved by the Board of Directors and approved by the stockholders at the 2012 Annual Meeting on July 10, 2012. The 2012 Plan originally reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, SARs, and other stock awards (i.e., performance shares and performance units). In May 2012, the Board of Directors approved an amendment to the 2012 Plan to increase the number of shares of the Company’s common stock reserved for issuance to 2,500,000 shares. In October 2019, the Board of Directors approved amendments to the plan, subject to ratification by the stockholders, which occurred at the Company’s 2019 Annual Meeting of Stockholders on November 21, 2019. As of February 28, 2023, there were 242,214 service-based options issued, 129,729 service-based restricted common shares granted, 530,851 performance-based and 116,218 market-based restricted common shares granted under the 2012 Plan. As of November 30, 2022, there were 242,214 service-based options issued, 129,729 service-based restricted common shares granted, 530,851 performance-based and 116,218 market-based restricted common shares granted under the 2012 Plan. As of February 28, 2023, there were no shares available for future issuance under the 2012 Plan.

On April 8, 2022, the Board of Directors of the Company adopted the 2022 Equity Incentive Plan (the “2022 Plan”) to provide incentive compensation to the Company’s employees, independent directors and independent contractors. The plan was approved by

the Company's stockholders on October 3, 2022 at the Company’s 2022 Annual Meeting. The 2022 Plan reserves 1,500,000 shares of the Company’s common stock for issuance pursuant to stock options, restricted stock, SARs, and other stock awards (i.e., performance shares and performance units). As of February 28, 2023, there were 176,100 service-based options issued and 475,000 market-based restricted options granted. As of November 30, 2022, there were 63,100 service-based options issues and 400,000 market-based restricted options granted. As of February 28, 2023, there were 848,900 shares available for future issuance under the 2022 Plan.

Service-based vesting condition options

The fair value of each option award is estimated on the date of the grant using the Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatility is based on the historical volatility of the Company’s stock over the most recent period commensurate with the expected life of the Company’s stock options. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected term of options granted to employees is based upon historical exercise data. Expected dividends are based on the historical trend of the Company not issuing dividends.

There were 113,000 and 0 options granted during the three months ended February 28, 2023 and 2022, respectively.

Variables used to determine the fair value of the options granted for the three months ended February 28, 2023 are as follows:

 

 

 

 

Three months ended

 

 

 

February 28,

 

 

 

2023

Weighted average values:

 

 

 

Expected dividends

 

 

0%

Expected volatility

 

 

55.00%

Risk free interest rate

 

 

3.87%

Expected life

 

 

5 years

 

Stock option activity for options with only service-based vesting conditions for the three months ended February 28, 2023, was as follows:

 

 

 

 

 

 

Weighted

 

 

Weighted
Average
Remaining

 

 

 

 

 

 

 

 

 

Average

 

 

Contractual

 

 

Aggregate

 

 

 

Options

 

 

Exercise
Price

 

 

Term
(Years)

 

 

Intrinsic
Value

 

Outstanding at November 30, 2022

 

 

329,314

 

 

$

8.36

 

 

4.68

 

 

$

37,250

 

Granted

 

 

113,000

 

 

 

4.68

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Expired/forfeited

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at February 28, 2023

 

 

442,314

 

 

$

7.42

 

 

 

4.54

 

 

$

20,750

 

Exercisable at February 28, 2023

 

 

320,671

 

 

$

7.48

 

 

 

4.46

 

 

$

20,750

 

 

The aggregate intrinsic value represents the total value of the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options that would have been received by the option holders had all option holders exercised their options on either February 28, 2023 or November 30, 2022 as applicable. The intrinsic value of the Company’s stock options changes based on the closing price of the Company’s stock.

During the three months ended February 28, 2023, the Company did not issue any common shares to option holders.

During the three months ended February 28, 2022, the Company issued 10,000 common shares to option holders who exercised options for $32,000.

Significant option groups outstanding and exercisable at February 28, 2023 and related price and contractual life information are as follows:

 

 

 

Outstanding

 

 

Exercisable

 

 

 

 

 

 

Weighted
Average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

 

Weighted

 

 

 

 

 

Weighted

 

Range of Exercise Prices

 

Outstanding

 

 

Contractual
Life
(Years)

 

 

Average
Exercise
Price

 

 

Outstanding

 

 

Average
Exercise
Price

 

$3.01 to $4.00

 

 

30,000

 

 

 

2.50

 

 

$

3.13

 

 

 

30,000

 

 

$

3.13

 

$4.01 to $5.00

 

 

113,000

 

 

 

4.85

 

 

$

4.68

 

 

 

50,000

 

 

$

4.62

 

$6.01 to $7.00

 

 

14,433

 

 

 

7.94

 

 

$

6.50

 

 

 

8,249

 

 

$

6.51

 

$7.01 to $8.00

 

 

194,781

 

 

 

4.71

 

 

$

7.63

 

 

 

180,829

 

 

$

7.60

 

$9.01 to $10.00

 

 

29,000

 

 

 

5.02

 

 

$

9.37

 

 

 

9,166

 

 

$

9.31

 

$12.01 to $13.00

 

 

16,653

 

 

 

7.48

 

 

$

12.54

 

 

 

12,799

 

 

$

12.58

 

$13.01 to $14.00

 

 

44,447

 

 

 

1.82

 

 

$

13.50

 

 

 

29,628

 

 

$

13.50

 

 

 

442,314

 

 

 

4.54

 

 

$

7.42

 

 

 

320,671

 

 

$

7.48

 

 

A summary of the status of the Company’s non-vested options as of February 28, 2023, and changes during the three months ended February 28, 2023, is presented below:

 

 

 

 

 

 

Weighted
Average

 

 

 

 

 

 

Grant-Date

 

 

 

Options

 

 

Fair Value

 

Non-vested at November 30, 2022

 

 

95,486

 

 

$

4.42

 

Granted

 

 

113,000

 

 

 

2.19

 

Vested

 

 

(86,843

)

 

 

3.17

 

Forfeited

 

 

 

 

 

 

Non-vested at February 28, 2023

 

 

121,643

 

 

$

3.24

 

 

As of February 28, 2023, there was approximately $316,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Plan, 2012 Plan and the 2022 Plan. The cost is expected to be recognized over a weighted-average period of 2.05 years as of February 28, 2023. The total fair value of shares vested during the three months ended February 28, 2023 was approximately $275,000.

 

Performance and market-based vesting condition options

On April 8, 2022, the Company granted 400,000 market-based vesting condition options to David Portnoy, Mark Portnoy, and Oleg Mikulinsky in the amounts of 280,000, 100,000, and 20,000, respectively. For market-based vesting condition options, accounting principles do not require that the market condition be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. The exercise price of the options is $12.27 and the calculated fair value of the options is $2.79. These stock options vest immediately when the price of the Company's stock reaches $25.00 per share during the seven-year option term. The grant of these options was approved by the Company's stockholders on October 3, 2022 at the Company’s 2022 Annual Meeting. As of February 28, 2023 and February 28, 2022, the Company recognized approximately $96,000 and $0, respectively, in compensation cost and is reflected as selling, general and administrative expense in the accompanying consolidated statement of income. As of February 28, 2023 and November 30, 2022, there was approximately $767,000 and $863,000, respectively, of unrecognized compensation cost to be recognized over the remaining requisite service period of 1.96 years.

On December 23, 2022, the Company entered into new two-year employment agreements (the "Agreements"), effective December 1, 2022, with David Portnoy and Mark Portnoy. Per the Agreements, David Portnoy and Mark Portnoy were awarded a signing bonus of a 5-year option to acquire 50,000 and 25,000 shares, respectively, of the Company's common stock, exercisable only if the Company's stock has a closing price at least once during the life of the option above $8.00. These options are considered to be market-based vesting condition options and accounting principles do not require the market condition to be met in order for the compensation cost to be recognized. Fair value of these options has been determined using a Monte Carlo valuation approach and is being recognized over the requisite service period, regardless if the market condition will be met. The exercise price of the options is $4.30 and the calculated fair value of the options is $1.76. These stock options vest immediately when the price of the Company's stock

reaches $8.00 per share during the five-year option term. As of February 28, 2023, the Company recognized approximately $15,000 in compensation cost and is reflected as selling, general and administrative expense in the accompanying consolidated statement of income. As of February 28, 2023 and November 30, 2022, there was approximately $117,000 and $0, respectively, of unrecognized compensation cost to be recognized over the remaining service period of 1.36 years.